The main predisposing factor for developing rheumatoid arthritis (RA) is found in a patient's genetic background. Over 100 genetic variants have been associated with RA risk, but the functional role of the vast majority of them is yet to be explored. This is largely due to the fact that around 90% lie outside traditional protein coding regions of the genome and, therefore, their potential role in pathological mechanisms is not obvious. There is now strong evidence that disease associated non-coding variants are involved in transcriptional regulation, enriched in cell type and stimulus-specific enhancer regions, and are capable of influencing their target genes through long-range chromatin interactions. With the goal of finding disease causing genes and, ultimately, potential drug targets, we characterized chromatin interactions at all associated regions for four autoimmune diseases (RA, juvenile idiopathic arthritis, psoriatic arthritis and type 1 diabetes) and their functional targets in B-and T-cell lines. We found numerous looping interactions between disease-associated SNPs and their potential targets which in many cases were not the nearest gene but more compelling candidate genes often situated several megabases away. Our results showed that a number of regions associated with different autoimmune diseases interact with each other and the same promoter suggesting common autoimmune gene targets. For one of these regions, 6q23, the association was initially assigned to TNFAIP3, the closest gene. However, CHi-C data showed that the DNA fragment containing the associated SNPs interacts through chromatin looping not only with TNFAIP3, but also with IL20RA, located 680 kb upstream. The risk allele of the most likely causal SNP, rs6927172, is correlated with both a higher frequency of interactions and increased expression of IL20RA, along with stronger binding of both the NFkB transcription factor and chromatin marks characteristic of active enhancers in T-cells. The IL20RA gene encodes one of the subunits of the IL-20 receptor. Cytokines of the IL-20 family and their receptors are upregulated in the synovium of RA patients. Very interestingly, a recent clinical trial has demonstrated that anti-IL-20 monoclonal antibody is effective in the treatment of RA. These findings show how functional evaluation of disease risk loci can help better translate GWAS findings into biologically meaningful mechanisms of disease and validate existing therapeutic targets or suggest potential new ones. Disclosure statement: The author has declared no conflicts of interest.
Disclosure statement: I.I.G.: Honoraria: UCB.
I38. BIOLOGICS AND SAFETY ISSUES GUIDELINE
Christopher R. Holroyd MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UNITED KINGDOM The use of biologic therapies has transformed the management of inflammatory arthritis, with disease remission becoming an increasingly achievable goal. Although efficacious, biologic therapies are not without potential risk; hence it is important that clinicians are aware of these risks and ensure that appropriate precautions are taken to minimize them. The objective of this guideline is to provide evidence based recommendations for the safe prescription of biologic therapies approved by NICE for the management of inflammatory arthritis (RA, psoriatic arthritis and ankylosing spondylitis). This guideline has been developed in line with BSR's guideline protocol and supersedes the 2010 BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Disclosure statement: The author has declared no conflicts of interest.
I39. MANAGEMENT OF GIANT CELL ARTERITIS

Bhaskar Dasgupta
Rheumatology, Southend University Hospital NHS Trust, Westcliffon-sea, UNITED KINGDOM Giant cell arteritis is classified as a large-vessel vasculitis affecting predominantly older people and women more than men. Inflammation of the vascular wall, observed by histological examination of a temporal artery biopsy, is associated with intimal hyperplasia; this may result in vessel occlusion and end-organ ischaemia, producing manifestations that include jaw claudication and irreversible sight loss which almost always occurs before start of glucocorticoid (GC) therapy. For this reason, GCA is considered a medical emergency requiring fast track immediate treatment with high-dose GC. The vasculitis may also cause a systemic inflammatory syndrome, sometimes called the syndrome of large-vessel vasculitis (LVV), in contrast to the cranial features of GCA which include headache, visual disturbance and jaw claudication. Frequently, however, clinical and imaging features of LVV are observed to coexist with histological features of temporal arteritis and/or cranial symptoms. Recent years have seen new evidence emerge regarding diagnosis and treatment of GCA and for this reason a major revision of the 2010 BSR guidelines was required. This Guideline developed using GRADE methodology is intended for clinicians involved in the care of GCA working in a primary or secondary care setting. The objective was to provide guidance on a diagnostic approach to GCA, to outline overarching principles of management, and to produce evidence-based recommendations regarding treatment. Takayasu arteritis is not covered by this guidance. Uncomplicated polymyalgia rheumatica (PMR) is outside the scope of this guideline; readers are referred to the BSR endorsed 2015 ACR/EULAR guidance on management of PMR. There is no evidence that one type of intensive treatment is more effective than another. Head-to-head trials of combination DMARDs against biologics with methotrexate suggest similar efficacy. Triple therapy with methotrexate, sulfasalazine and hydroxychloroquine is the most studied and potentially the most effective DMARD combination. There is insufficient evidence to suggest that one biologic is substantially different to another. There is generally more toxicity with intensive treatment strategies, but the differences are usually small; an exception is the greater toxicity of methotrexate with ciclosporin.
Results: The cost-effectiveness of biologics has been studied by multiple groups; the findings vary substantially. In established RA patients who have failed to respond to methotrexate some studies report the relative cost-effectiveness of biologics is just within the accepted fundable threshold (£30,000/quality adjusted life year) but many studies find they exceed the threshold. In early RA biologics usually exceed the accepted fundable threshold. Studies of combination DMARDs invariably find these approaches are more cost-effective than biologic treatments. Conclusion: The balance of current evidence suggests when patients need intensive treatment using combination DMARDs before biologics with methotrexate is equally effective and more cost-effective. The DMARD combination with the strongest evidence base is triple therapy. However, substantial uncertainties about optimal management approaches remain, particularly in early RA. In this setting not all patients need intensive treatment, not all patients respond to one type or even any type of intensive treatment, and alternative strategies, such as achieving drug-free remission using intensive initial biologics, may be highly costeffective in the fullness of time. The role of intensive treatments in active RA still requires substantial further research. Disclosure statement: The author has declared no conflicts of interest.
I41. BIOSIMILARS
Peter Taylor
Rheumatology, University of Oxford, Oxford, UNITED KINGDOM Biologic drugs are proteins produced in living cells. Some are relatively small in terms of molecular weight, such as insulin. Larger in size are growth factors and larger still are complex large proteins such as monoclonal antibodies or fusion proteins with a molecular weight on the order of 150 kDa. Proteins have a primary amino acid sequence and then adopt secondary and tertiary conformations depending on how the molecule folds in three-dimensional space. Furthermore, after translation of a primary amino acid sequence from mRNA, so called posttranslational modifications of the protein take place. These include, for example, addition of sugar molecule side chains, deamidation and methionine oxidation. The resulting protein is thus a large and complex structure. The remarkable efficacy and overall safety of originator biologic targeted therapies in the field of rheumatology has led to major changes in the management of several chronic inflammatory musculoskeletal conditions since their availability at the beginning of the millennium. However, drawbacks of biologics in general include the need for parenteral administration of a protein based drug but above all, the very high cost of originators. As originator biologics have come off patent, there has been an opportunity to generate copies. But unlike generic, small molecule drugs, which are exact copies of the molecular configuration of the originator (such as aspirin, for example), the complexity of large molecular weight proteins and post-translational modification is such that exact copies cannot be made although the same primary amino acid sequence can be copied. This gives rise to the possibility of making similar copies of an originator biologic, potentially without the need for a full drug development programme and associated costs, and thus make more cost competitive biologic versions. But because post-translational modifications can alter protein function, it is very important when manufacturing such copies of biologics that the process is tightly regulated to ensure safety. The designation biosimilar only applies to biologic drugs that fulfil stringent regulatory requirement in Europe or North America. In this lecture, we will discuss how biologics are produced, and explore together the pre-clinical and clinical trial criteria required for regulatory designation of a biosimilar drug. Finally, in this session on cost effective treatments in RA, the implications of biosimilars for cost savings in the NHS will be considered. 
I44. COMPLEX CRYSTAL ARTHRITIS
Edward Roddy
Research Institute for Primary Care and Health Sciences, Keele University, Stoke-on-Trent, UNITED KINGDOM Gout and calcium pyrophosphate crystal deposition (CPPD) are common clinical problems encountered by rheumatologists. Gout is the most common inflammatory arthritis, affecting 2.5% of adults in the UK, and its prevalence and incidence continue to rise. CPPD is a common aged-related phenomenon and affects as many as one in six people aged over 80 years in the UK. Despite the high prevalence of gout and an excellent understanding of its aetiology and pathogenesis, it remains poorly managed by GPs and hospital specialists including rheumatologists. Only 35-40% of patients with gout are offered definitive curative urate-lowering therapy (ULT), and of those treated with ULT, only 45% managed by rheumatologists achieve a target serum uric acid level below 360 mmol/L. However, rheumatologists often see the most complex patients in whom gout is commonly accompanied by chronic kidney disease and heart disease, presenting a significant barrier to treatment. CPPD remains neglected, being hugely under-researched and hampered by a dearth of specific treatment options for the most severely-affected patients. Using illustrative cases, this talk will offer practical advice to guide the management of the most complex patients with gout in relation to commonly-occurring clinical challenges, namely, severe chronic kidney disease, solid-organ transplantation, and choice of drug therapies beyond allopurinol. The causes of troublesome, recurrent CPPD will be reviewed and options for long-term management discussed. Disclosure statement: The author has declared no conflicts of interest.
I45. ANKYLOSING SPONDYLITIS: ANTI-TUMOUR NECROSIS FACTOR AND BEYOND
Raj Sengupta
Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, UNITED KINGDOM Tumour necrosis factor inhibitor (TNFi) therapy has been the cornerstone of the treatment of axial spondyloarthritis (axSpA) over the last decade. However, some patients do not respond to these drugs and require consideration of alternative therapies. Until February 2016, the National Institute for Health and Clinical Excellence allowed clinicians to only use 1 TNFi drug for axSpA patients. The development and availability of newer biologics such as Secukinumab (IL17 blocker) has provided an alternative to TNFi treatment. The treatment pathway for these patients is evolving and understanding the timing of biologic initiation and the sequence of biologics prescribed is important. Disease modification requires further exploration in axSpA. The halting of radiographic progression in axSpA remains unexplained and the timing of biologic initiation may be a crucial factor in explaining this.
TNFi has been very effective for the majority of axSpA patients with regard to pain, stiffness and general well being. However, a number of other aspects of the disease which are important to axSpA patients such as sleep, work ability, flares and fatigue need to be measured and treated to ensure a holistic approach to the treatment of axSpa. Through a series of cases we will explore the above points to discuss current approaches to optimize management of patients with axSpA. Most individuals with rheumatoid arthritis present with aberrant body composition (i.e. depleted muscle mass, and increased adiposity, especially around the trunk). This feature of RA, referred to as rheumatoid cachexia (RC), is primarily driven by inflammation (principally the pro-inflammatory cytokine, TNF-a) and exacerbated by sedentary lifestyle. RC is a major contributor to the disability and increased co-morbidity risk (CVD, TIID, metabolic syndrome) that characterize RA, and it is our belief that physical function and comorbidity risk in RA patients cannot be fully restored unless body composition is corrected. This belief is supported by results from our recent study comparing body composition and objectively measured physical function in 82 RA patients, who had been exclusively treated by current Treat-to-target (T2T) strategies (i.e. diagnosed and commenced treatment post-January 2008), with 85 age-and sexmatched healthy sedentary controls. Despite tight control of inflammation and responsiveness to treatment (mean DAS28 ¼ 2.8, half were in remission i.e. DAS28 <2.6), our current patients presented with the same degree of muscle loss, whole-body and trunk adiposity and disability as pre-T2T RA patients. To put the degree of functional impairment into perspective, our successfully treated RA patients, who had a mean age of %60 years, had the function of healthy individuals aged %85 years. These results also support the idea that RC is established before diagnosis of RA and the initiation of treatment; and, since none of the DMARDs or biologics used to treat RA are anabolic, provides a likely reason for the inability of current treatment strategies to improve body composition and, consequently, restore function. This conclusion logically emphasizes the requirement of adjunct treatments for RA patients that aim specifically at increasing muscle mass and reducing adiposity to facilitate restoration of function. In this talk, the efficacies of potential adjunct treatments for RC including anti-TNF's, anabolic nutrition (dietary protein and creatine supplementation), anabolic steroids, and high-intensity exercise in improving body composition and physical function will be discussed. Disclosure statement: The author has declared no conflicts of interest.
I47. SMOKING
Patrick Venables
Kennedy Institute of Rheumatology, Oxford University, Oxford, UNITED KINGDOM
No abstract submitted
Disclosure statement: The author has declared no conflicts of interest.
I48. OBESITY AND ITS IMPACT ON RHEUMATOID ARTHRITIS: A PUBLIC HEALTH CONCERN THAT CANNOT BE IGNORED
Grainne Colligan
Centre for Primary Care and Public Health, Queen Mary University of London, London, UNITED KINGDOM Background: The UK rheumatology community serves an ageing and ethnically diverse population, with a growing public health concern about obesity. Overweight and obesity contribute to 2.8 million preventable deaths annually. A raised Body Mass Index (BMI) in those with Rheumatoid Arthritis (RA) can have a significant negative impact on clinical outcomes. The aim of the study was to examine patients' and providers' perceptions of obesity and potential barriers to participation in a future weight management programme to contribute to an appropriate intervention design. Methods: Qualitative semi-structured interviews were carried out with 11 patients with RA and one focus group was held with 8 members of a multi-disciplinary team working in one tertiary Rheumatology outpatient clinic. Framework analysis contributed to the inductive thematic analysis, and was employed to assist with the identification of the emergent codes and final themes.
Results: Three core themes from the semi-structured interviews were ascertained: the psycho-social impact of living with RA and obesity, challenges of living with RA and obesity and considerations for future weight management programmes. The Focus group analysis also identified three core themes: micro-dynamics between patient and provider, meso-dynamics between providers and the health care service and the social and political context of obesity as a public health concern. Conclusion: Perceptions of obesity and weight gain and associated barriers to participating in weight management programmes differ significantly between patients and providers. Patients require a holistic approach to weight management by clinicians and the acknowledgement of the significant psycho-social impact of a dual diagnosis of RA and being overweight or obese. In contrast, providers seem reluctant to address weight increase with patients and require education and support at an individual and institutional level to integrate weight management into routine care. Disclosure statement: The author has declared no conflicts of interest. For effective self-management, patients need to learn new skills requiring a change in behaviours or thinking. However, many health professionals lack expertise in behaviour change techniques and use a more didactic, information-giving approach, but such approaches are known to be ineffective. The aim of this session is for delegates to understand more about how to facilitate behaviour change through motivational interviewing and the use of daily activity diaries. The session will include demonstrations and a chance to practice with your colleague in a supportive environment. Ã 15, etc. As these antibodies are gene products, such associations have potential mechanistic implications, although yet to be elucidated. An immune-mediated necrotizing myopathy is a rare complication of statin use, and statistically associated with HLA-DR1 Ã 11. HLA-1 molecules are manufactured on the inside of the endoplasmic reticulum (ER), and take protein waste to the cell surface, and HLA up-regulation is a recognized feature of myositis, including with statin use. Interestingly, the target of statin therapy, HMG-CoA reductase, also sits on the inside of the ER, alongside cytochrome P450. These enzymes will both be under polymorphic genetic control, so it is intriguing to speculate that interactions of their phenotypes and with HLA molecules and statins within the ER could cause problems. The many novel findings made by the collaborations listed emphasize their importance, and pose important mechanistic questions which, when answered, could facilitate the development of more effective novel therapies. Synovial fibroblasts (SF) are the main resident cells of the joint synovium and play a central role in joint inflammation and destruction in rheumatoid arthritis. Our latest research shows that SF from different joints are distinct cell types, with joint specific transcriptomes, epigenomes and functions, creating a unique environment in each joint. In particular, transcripts that are crucial for embryonic limb development appear as major determinants of the joint-specific identities of SF. Their differential expression between joints might explain the characteristic appearance of jointspecific patterns of arthritis. However, not only in health, also in disease the pathways that are activated in the different joints substantially differ, which might influence their therapeutic response. In future, these differences probably should be taken into consideration for the treatment of patients with arthritis. Disclosure statement: The author has declared no conflicts of interest. Persistent pain is the primary symptom of people living with rheumatology condition. The British Pain Society defines persistent pain as ''a common complex sensory, emotional, cognitive and behavioural long-term health condition, which occurs when pain cannot be resolved by available medical or other treatments.'' When a physical manifestation of the cause of this ongoing pain is also lacking, then the patient may feel disbelieved and confused. For the clinician, selecting therapeutic interventions based on the underlying mechanisms that drive this persistent pain can be a challenge. Both the patient and clinician may experience a sense of hopelessness and helplessness in this scenario. Additional symptoms associated with persistent pain, such as altered perception of the size and shape of the painful body part, are not routinely inquired about in clinical appointments, but may be impact sensory and motor function. The simple act of moving a limb requires a complex interaction between an ability to accurately sense the world around us, timely and accurate relay of that information to the brain, access to information about relevant previous experience, and the planning and execution of a response to that new knowledge. When these sensory and motor pathways become disrupted, as in the presence of chronic pain, discordances in sensorimotor function may generate pain and other changes in sensory perception and performance. This Droitwich lecture will discuss the less obvious symptoms of altered sensory perception, such as phantom swelling of a joint or limb, which people with persistent pain commonly describe. It will consider how these complex altered perceptions influence motor planning, emotional, cognitive and behavioural aspects, and propose that this experience of pain perception is about a person's expectations, informed by a person's previous experience. Novel therapeutic interventions will be discussed, which have demonstrated that when these expected perceptions are changed via multidisciplinary rehabilitation techniques, then normal sensory and motor function can be restored and chronic pain relieved. 
I49. SKILLS TO SUPPORT BEHAVIOUR CHANGE
I57. SYNOVIAL FIBROBLASTS AS THERAPEUTIC TARGETS
ESSENTIALS: SYMPTOM MANAGEMENT I62. MY EYES HURT!
Alastair Denniston
Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UNITED KINGDOM Many rheumatic diseases have ocular complications. These range from relatively mild ocular surface problems to potentially blinding intraocular and orbital disease. It is important to know which ophthalmic conditions can be associated with which rheumatic disease and to know what needs referral and how urgently. This talk will provide a very practical approach to the recognition and management of common eye presentations in the rheumatological clinic. Disclosure statement: The author has declared no conflicts of interest. 
I63. BREATHLESSNESS: CAUSE OR CONSEQUENCE OF DISEASE
I69. DERMATOMYOSITIS IN ADOLESCENCE
John Ioannou Adolescent and Young Adult Rheumatology, University College London, London, UNITED KINGDOM
Adolescence is a time of immense biological and psychosocial changes and hence a time of vulnerability. Juvenile onset dermatomyositis (JDM) may require ongoing long term treatment as the child progresses through adolescence, and indeed may prevent during this developmental stage. The talk will explore the key clinical phenotypic differences between JDM and adult onset dermatomyositis, and specifically focus on adolescent specific issues that are relevant to the management of JDM in this age group. 
ESSENTIALS: EXPERTS IN THE FIELD I71. EHLERS-DANLOS AND COLLAGEN VASCULAR DISORDERS
Glenda Sobey EDS National Diagnostic Service, Sheffield Children's NHS Foundation Trust, Sheffield, UNITED KINGDOM
The term Ehlers-Danlos Syndrome (EDS) refers to a group of inherited connective tissue disorders. In many subtypes the genetic basis is now known. The skin, joints, blood vessels and hollow organs can all be affected with consequences varying from mild features to severe life threatening events. The accurate diagnosis of EDS allows specific management, family screening and prenatal diagnosis. The rheumatologist can play an important role in the diagnosis of EDS and is central to the ongoing management of many EDS patients. This talk will address practical aspects of looking after patients with the rare and complex types of EDS based on experience in the EDS Specialist clinic Disclosure statement: The author has declared no conflicts of interest.
I72. SUSPECTED SARCOMA: WHAT DOES THE RHEUMATOLOGIST NEED TO KNOW? HOW YOU CAN MAKE A DIFFERENCE TO PATIENTS WITH A RARE CANCER
Jonathan Gregory
Orthopaedic Oncology, Royal Orthopaedic Hospital, Birmingham, UNITED KINGDOM Bone and soft tissue sarcomas are a rare but devastating group of cancers that arise in the connective tissues of the body, most commonly in the limbs. They are a heterogeneous group of tumours, but the common feature is that they often present as a lump. As such many different health professionals may see patients who present with a lump who in fact have a sarcoma. This variation in diagnostic journey often engenders significant delays to diagnosis. The size of tumours at diagnosis is directly linked to outcome therefore any delay in diagnosis adversely affects a patients chances of survival. How should a clinician approach a lump? What diagnostic algorithm should be applied to bone and soft tissue lumps? How do I triage cases so as to avoid overinvestigation of some cases but not miss the patient with cancer? The aim of this lecture is to answer these questions. It is the intention to provide an overview of these tumours so that rheumatologists are aware of the part they can play in the diagnosis of these cases. At the end of the lecture attendees should feel they have a safe approach to the management of lumps. Specific attention will be paid to tumours of the hands and feet and other presentations, which may be seen in rheumatology clinics. Sarcoma is rare and disproportionately affects younger populations compared to other cancers. Prompt diagnosis saves lives and by raising awareness of this group of cancers it is hoped the rheumatologists who attend this session will be able to make a real difference to patients who suffer from this rare cancer. Early inflammatory arthritis clinics are the gateways for diagnosing and treating patients within three month period from symptom onset. The early intervention has been shown to reduce the disease impact on patients. In order to evaluate whether rheumatology services are delivering the key standards set by the National Institute for Health and Clinical Excellence (NICE), the British Society of Rheumatology (BSR) conducted a national audit to survey the delivery of care. We analysed data to investigate the differences in ethnic groups. The findings suggest that there were differences between ethnic White British, South Asian and Afro-Caribbean patients. Despite presenting with similar times of symptom onset and disease severity, the South Asian patients were noted to express greater impact of the disease on functional disability, fatigue, emotional well-being, physical well-being and coping, and this could have an impact on the way patients perceive RA treatments. Our previous studies have shown that South Asian patients were less satisfied with information about disease and treatments. Furthermore, they were found to be less adherent to RA treatments than White British patients. In this session the audience will hear about the results and implications for practice. Disclosure statement: The author has declared no conflicts of interest.
I74. MAKING YOUR RESEARCH ACCESSIBLE, UNDERSTANDABLE AND MEANINGFUL TO PEOPLE WITH LOWER HEALTH LITERACY LEVELS
Jo Adams
Faculty of Health Sciences, University of Southampton, Southampton, UNITED KINGDOM Many research studies conducted within musculoskeletal services are not yet effective in recruiting harder to reach populations, such as those with lower health literacy, to participate in research. This has important implications. For qualitative studies, a wide range of people's experiences will be unreported and for quantitative trials results could be biased, non-generalizable and providing results that lack validity for a large proportion of the NHS patient population. For people with musculoskeletal conditions and lower health literacy levels this is particularly important as this population already has worse outcomes when using the NHS than people with higher health literacy levels. This is a timely issue to consider as it is reported that health professionals don't feel prepared or skilled in supporting people with lower levels of health literacy to engage with health services. This workshop presentation will consider that at each stage of the research cycle the process and procedure of developing, designing, implementing and disseminating research can benefit from consideration of strategies to engage people with lower health literacy. Early support and involvement of patient and public representatives can initially help in identifying processes that will facilitate engagement of harder to reach groups, from recruitment through to participation and follow-up. Use of local community lay, non-NHS routes to talk with people with lower health literacy are effective routes to gain early feedback and commentary on research processes and procedure to help design and develop accessible research processes that engage and attract harder to reach populations. Liaison with local authority and public health resources can help raise awareness of the relevance of research beyond usual NHS clinical routes. The research process can always be improved by the clarification and simplification of language used on participant focused information. Simple, uncomplicated and friendly approaches on information sheets and trial advertisements can gain ethical approval and can facilitate understanding and engagement of harder to reach populations and effective recruitment processes. Ensuring that sufficient time is costed in to research to support recruitment for all patients is advised. Finally, engaging harder to reach populations in research will be facilitated by ensuring that research findings are not only disseminated in scientific and professional publications but also via lay routes. Finding patient publications, popular press items and local news pieces will help to raise awareness of musculoskeletal research with the people it purports to serve. Disclosure statement: The author has declared no conflicts of interest.
I75. STRATEGIES FOR ENGAGING MEN IN RHEUMATOLOGY RESEARCH
Caroline Flurey Health and Applied Sciences, University of the West of England, University of the West of England, Bristol, UNITED KINGDOM Quantitative research is sometimes referred to as hard science or considered more scientific than soft qualitative research. Considered with conceptualizations of idealized gender roles of the hardy, stoic and enduring male and the soft, subservient female it is perhaps unsurprising that feminist research is predominantly focused on women's issues. In contrast, qualitative interviews are viewed as a threat to masculinity and a potentially problematic research method for many men who do not readily express themselves. However, qualitative research is becoming recognized as an ideal tool for exploring patient experience and the complexities of men's subjective lives. The growing body of qualitative research in men's health indicate that counter to previous assumptions, given appropriate circumstances, men will talk about their health. This presentation will provide suggestions for engaging men in research at both recruitment and data collection stages, focusing particularly on qualitative research. Disclosure statement: The author has declared no conflicts of interest.
STRIVING FOR QUALITY IN EPIDEMIOLOGICAL RESEARCH I76. USE OF ROUTINE CLINICAL DATA AND PRIMARY CARE RECORDS FOR OBSERVATIONAL RESEARCH
Daniel P. Alhambra Nuffiled Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford University, Oxford, UNITED KINGDOM NHS computerized records and other routinely collected data are increasingly used for observational research in rheumatology. These contain information on potentially all patients and settings/treatment centres, both in primary and secondary care. In addition, they are collected in actual practice conditions, which makes them particularly interesting to answer certain research questions with a focus on those patient sub-groups often under-represented in other types of studies (e.g. randomized controlled trials). We will report on the available existing sources of routinely collected data including opportunities for multi-national collaborations, to then discuss the strengths and limitations of any research studies based on such datasets. Finally, we will cover some illustrative examples on the use of routinely collected data in recently published papers covering topics of interest to the field of rheumatology and musculoskeletal sciences. Disclosure statement: D.P.A.: Honoraria: Amgen. Grants/research support: Servier, Amgen.
I77. QUALITY VERSUS FRAUD IN CLINICAL RESEARCH: HOW RESEARCH METHODOLOGY CAN INFLUENCE RESEARCH CONCLUSIONS
Kimme Hyrich Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, UNITED KINGDOM Observational research represents a key component of understanding outcomes within medicine. Its role is even more crucial when studying a chronic disease over a long period or the risk of rare side effects of a medicine, where the design of clinical trials is not appropriate. However, differences in the way data are collected and compared within studies can lead to markedly different research conclusions about disease or treatment outcomes. This talk will use real research examples to show the importance of considering common methodological pitfalls within data collection and analysis to demonstrate how different conclusions can be reached in our attempts to answer similar research questions. Disclosure statement: K.H.: Honoraria: Pfizer, AbbVie.
I78. WHY ARE CLASSIFICATION CRITERIA NOT APPROPRIATE TO MAKE A DIAGNOSIS?
Desiree van der Heijde Leiden University Medical Center, Leiden, THE NETHERLANDS Most rheumatological diseases are based on a complex of signs, symptoms and abnormal findings in the lab and on imaging. Only rarely a single test is sufficient to make a diagnosis such (e.g. an elevated glucose level fulfilling certain definitions in diabetes mellitus). Making a diagnosis in rheumatology is based on pattern recognition. The more positive parameters after history taking, physical examination, and additional lab work and imaging, the more likely a certain diagnosis is. Also negative findings should be taken into account and finally a diagnosis with a certain likelihood can be made. This can only be done after exclusion of other mimicking diagnoses. Classification criteria are checklists and result in a yes/no answer: patients fulfill the criteria or not, the number of positive parameters is irrelevant and negative findings are not taken into account. There is no explicit need to exclude differential diagnoses. Classification criteria are used to define homogeneous groups to be included in research and should only be applied in patients that already have the diagnosis of the disease. Diagnostic criteria in rheumatology do not exist and both EULAR and ACR have decided that they will not develop diagnostic criteria as these are insufficiently valid. Practicing rheumatologists are inclined to use classification criteria in clinical practice to make/confirm a diagnosis. Why is this not appropriate? During the development of classification criteria, they are validated against an external standard, frequently this is an expert diagnosis. Test characteristics of good classification criteria are e.g. a sensitivity of 85% and specificity of 87%. Inherently, 15% of patients are falsely not classified and 13% is falsely classified. Corresponding positive Likelihood Ratio (LR þ ) is 6.5 and negative LR (LR À ) is 0.17. If classification criteria would be applied as diagnostic criteria, you could calculate the diagnostic performance of this test. The most important characteristic of a test is the positive (and negative) predictive value and this is largely dependent on the pretest probability (i.e. the prevalence) and is calculated by using the LR þ (or LR À ). Applying the same test in the general population (low pretest probability) would lead to an unacceptably high percentage of falsely diagnosed cases, while this would perform well in a specialized tertiary referral centre (high pretest probability). Striking examples of the consequences of applying classification criteria wrongly as diagnostic criteria of the ASAS axial SpA criteria and the CAPS criteria (which are even published as diagnostic criteria) will be presented during the lecture. Disclosure statement: The author has declared no conflicts of interest.
THE CHALLENGES OF RARE RHEUMATIC DISEASES I79. CHALLENGES OF DIAGNOSING AND MANAGING PATIENTS WITH RARE DISEASES
Robert Moots
Musculoskeletal Biology, University of Liverpool, Liverpool, UNITED KINGDOM
The days have thankfully gone when physicians collected fascinating rare conditions to impress their staff and students. These patients were seen regularly and, sadly, merely observed while their condition inevitably deteriorated as either no treatment was available (with no research under way to address this) or newly emerging and potentially useful treatments were not applied. Today, we are all too busy with the demands of running services for conditions that we know, understand and can even (for once) treat, to be able to effectively care for many patients with rare rheumatic diseases. In this session, we will use the example of Behç et's syndrome, a very rare disease in the UK, to illustrate how the care of patients with complex rare diseases can be transformed from merely observing fascinomas to delivering world class, cutting edge management. This depends upon an effective partnership between specialist (often National) centres and local Rheumatology units, allowing patients to be cared for effectively, close to their homes, with appropriate specialist expertise and backup readily available -including funding for expensive therapies without the need for penalizing bureaucracy. We will discuss the importance of being able to recognize rare conditions, identify referral Centres and how we can work effectively in partnership with the patient and referral centre to deliver the best care. Disclosure statement: The author has declared no conflicts of interest.
I80. THE CHALLENGES FACED BY PATIENTS WITH A RARE RHEUMATIC DISEASE: THE PATIENT PERSPECTIVE
John Mills
Chair, Vasculitis UK, Matlock, UNITED KINGDOM John suffers from vasculitis -a rare rheumatic autoimmune disease. In this presentation he will explore his personal journey with vasculitis and its consequences, leading on to the problems which are common to many similar rare diseases -including delayed recognition and diagnosis, unclear treatment pathways and problems accessing modern more effective and safer drugs. After discussing the personal, family and social consequences of these diseases, he will conclude by emphasizing the importance of alliances, registries and collaborative research for all rare diseases. Disclosure statement: The author has declared no conflicts of interest.
I81. HOW DO YOU EDUCATE PATIENTS WITH RARE RHEUMATIC DISEASES
Janice Mooney
School of Health Sciences, University of East Anglia, Norwich, UNITED KINGDOM How do you educate patients with rare rheumatic diseases? A disease is considered to be rare if it has a population prevalence of< 5 in 10 000.
There are a number of rare rheumatic conditions, including most of the vasculitides and many of the connective tissue disorders. Rare diseases pose numerous challenges to both healthcare professionals and patients. Many healthcare professionals have little knowledge or experience of rare conditions. The impact of a diagnosis of AAV is significant and patients will need information and advice in order to help them manage their disease. It is vital therefore that patients receive education and counselling to help them to self-manage and participate in informed decision making. This presentation will discuss the challenges that patients face during their therapeutic journey and how we as clinicians can improve this. subsequently relapse once treatment is withdrawn, suggesting that additional therapeutic targets responsible for complete resolution of chronic inflammation remain to be discovered. Inflammation results from the complex interaction between haematopoietic and stromal cells. Yet almost all current therapies target haematopoietic cells and ignore stromal cells, such as fibroblasts. Our work over the last decade has demonstrated that in addition to their well-known structural role in landscaping the microenvironment, fibroblasts modify the quality, quantity and duration of leucocyte accumulation within tissues They also contribute to the resolution of inflammation by normalizing chemokine gradients, thereby allowing infiltrating leucocytes to leave the tissue through the draining lymphatics. We have proposed that inflammation is contextual and since fibroblasts help define tissue topography we have suggested that fibroblasts represent an attractive, site specific therapeutic target. We now propose that fibroblasts exist in discrete subsets, some of which are pro-inflammatory while others, more functionally similar to MSC, are anti-inflammatory and regulate tissue homeostasis and organ repair. This has led to a therapeutic dilemma: which fibroblasts to delete and which to replace? Therefore a clear understanding of the biology and significance of fibroblast heterogeneity is essential to provide a coherent rationale for their targeting in the treatment of different rheumatic diseases. Disclosure statement: C.B.: Consultancies: Roche, GlaxoSmithKline. Grants/research support: GlaxoSmithKline, Roche, UCB, Actelion.
